The Pharma Data

SEPTEMBER 22, 2020

Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). and IL-18, which are believed to be a driving force behind several chronic inflammatory conditions.

Pharma Companies 52

Pharma Companies Small Molecule Pharmaceutical Companies Disease 52

thought leadership

MAY 29, 2023

Specialty pharma companies are focused on developing drugs for niche markets, such as rare diseases , cancer, and other complex conditions. In this blog post, we'll explore some of the key challenges of specialty pharma drug development project management and discuss strategies for overcoming them.

Drug Development 52

Drug Development Pharma Companies Drugs Disease 52

The Connected Lab

APRIL 8, 2020

To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. For complex diseases, this requires that researchers fully understand how molecules will interact with one another. 36 Pharma Companies Using Artificial Intelligence in Drug Discovery.”

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

DrugBank

JUNE 27, 2024

They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharma companies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.

Drugs 71

Drugs Pharma Companies Clinical Trials Computational Chemistry 71

The Pharma Data

SEPTEMBER 29, 2020

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas. At the time, Pfizer made a $33m equity investment in Sosei as part of the collaboration agreement.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Clinical Trials Small Molecule Pharma Companies 52

Drug Target Review

APRIL 19, 2024

The scientific founders have developed a pioneering method for drug discovery that applies to the research and design of new drugs effective against diseases that are incurable to date. Our ongoing research and development are poised to explore these avenues, aiming to address complex diseases with novel therapeutics.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

PPD

JULY 13, 2023

Data from the survey has produced enlightening insights about the priorities of both large and small/mid-size pharma companies that can be used to guide business decisions. Patient advocacy groups can create a valuable connection to potential research participants, especially for rare disease trials.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Clinical Research 52

H1 Blog

JUNE 7, 2023

Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. This is especially true for rare disease populations, where understanding the nuances between different patient cohorts is key to achieving positive outcomes. The Michael J.

Trials 52

Trials Clinical Trials Pharma Companies Clinical Development 52

The Pharma Data

JANUARY 17, 2021

Alzheimer’s disease has found itself in the top three most expensive diseases. The pharma company hoped to find success for troriluzole in multiple indications and had studies evaluating efficacy in generalized anxiety disorder (GAD), obsessive compulsive disorder, spinocerebellar ataxia and Alzheimer’s disease (AD). .

Pharma Companies 52

Pharma Companies Disease Treatment Trials 52

The Pharma Data

SEPTEMBER 11, 2020

While stories from news outlets indicate the peak of the infection has passed in most European countries, cases of the disease continue to rise in other parts of the world, especially Latin America and Africa. This week’s round up dives into developments from companies based in Australia and the US. “The Saama Technologies, Inc. ,

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

The Open Targets Blog

OCTOBER 24, 2023

OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs. We primarily work on immune system diseases, integrating data and analyses from OTG on a large scale. Amir Feizi and Ray Kamalika What inspired you to create Otargen?

Bioinformatics 63

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 63

The Pharma Data

SEPTEMBER 24, 2020

As part of the collaboration agreement, Oncimmune will characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including the autoimmune disease systemic lupus erythematosus (SLE).

Trials 40

Trials Clinical Trials Pharma Companies Disease 40

H1 Blog

JULY 30, 2024

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.”

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

Drug Target Review

JULY 11, 2024

Scientists and, increasingly, biotechs and pharma companies hope to create a more detailed map of the surfaceome, the entire cancer cell surface and its membrane-bound proteins. Selecting protein target candidates The DISCO team has a number of global SCLC experts, having published more than 100 papers collectively on the disease.

Therapies 56

Therapies RNA Pharma Companies Disease 56

Vial

DECEMBER 8, 2023

In this article by Vial CRO (Contract Research Organization), we will explore five anticipated ophthalmology therapies in 2024, offering valuable insights for biotech startups, CROs, pharma companies, clinical sites, and scientists planning to conduct clinical trials.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

The Pharma Data

JANUARY 31, 2021

At DeveloGen, Dr Dohrmann led the company to become an internationally recognised leader in metabolic diseases. Furthermore, Evotec developed innovative partnership models with academia, biotech and pharma companies to accelerate the translation of academic discoveries into promising co-owned product opportunities.

Science 52

Science Government Medical Schools International 52

Dark Matter Blog

JUNE 21, 2023

Then, we discover and optimize ligands to these RNA structures to generate small molecule medicines that will either work on their own, or as part of multifunctional drug modalities on targets that drive disease. Pharma companies interested in probing new ways to reach these once-undruggable targets are potential partners for Arrakis.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

Drug Target Review

OCTOBER 1, 2024

As a Medical Director with broad experience in clinical practice, I am deeply convinced that in pharma companies Medical Affairs will be a strategic leader at the centre of clinical development, identifying and addressing unmet patients, payers and policymakers’ needs that advance clinical practice and improve patient outcomes.

Doctors 97

Doctors Therapies Science Pharma Companies 97

Drug Channels

FEBRUARY 6, 2024

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and the Rare Disease Summit three influential access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships. What is Access USA?

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Pharma Companies Disease 40

The Pharma Data

DECEMBER 23, 2020

AIM announced in October that the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) clinical trial received IRB approval to include patients previously diagnosed with SARS-CoV-2 – which causes the disease COVID-19 – but who now demonstrate post-acute infection chronic fatigue-like symptoms. See: PLOS ONE ). AIM CEO Thomas K.

Clinical Trials 52

Clinical Trials Trials Virus Therapies 52

H1 Blog

JULY 5, 2023

In this blog post, we will explore how diversity impacts drug development , from pre-clinical stages to regulatory approvals, and what areas medical affairs professionals should consider for increasing diversity of thought from a broader stroke of healthcare providers (HCPs) and key opinion leaders (KOLs).

Clinical Trials 52

Clinical Trials Drugs Trials Drug Development 52

The Pharma Data

OCTOBER 20, 2020

MD Anderson has historically collaborated with biotechs and pharma companies to conduct cancer therapy research. 2 killer in America, just behind heart disease. Ochsner Health and LSU Health Shreveport have offered themselves as additional trial sites to increase patient access to studies. . Cancer is still the No.

Clinical Trials 52

Clinical Trials Therapies Pharma Companies Trials 52

Alta Sciences

MARCH 27, 2024

As if that isn’t enough, she is also working toward her PhD, with research focusing on the impact of supramental awareness on disease prevention, healing, and health. Opportunity leads me, and I just make sure I keep my eyes open.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

ACTO

NOVEMBER 25, 2024

“Our ambition is to become the first pharma company powered by artificial intelligence at scale, giving our people tools and technologies that focus on insights and allow them to make better everyday decisions. … Generative AI Generative AI (GenAI) refers to systems capable of creating new content, such as images, music, and text.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Pharmaceuticals 52

The Pharma Data

DECEMBER 11, 2020

SeaCube Containers , a pharmaceutical cargo trade company, has acquired 200 storage containers developed by Carrier and Sensitech to help address the anticipated increase in demand for refrigerated storage capacity and cargo visibility in support of Covid-19 vaccine distribution. Source link.

Vaccine 52

Vaccine Immune Response Pharma Companies Virus 52

The Premier Consulting Blog

OCTOBER 21, 2024

The FDA defines a serious condition as “a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.” This pathway has been used since 1992, benefiting both sponsors and patients in various disease areas including oncology, neurology, infectious disease, and rare disease.

Trials 52

Trials FDA Clinical Trials Disease 52

Nvidia Developer: Drug Discovery

FEBRUARY 14, 2024

The quest for new, effective treatments for diseases that remain stubbornly resistant to current therapies is at the heart of drug discovery. The quest for new, effective treatments for diseases that remain stubbornly resistant to current therapies is at the heart of drug discovery. This traditionally.

Drugs 86

Drugs Small Molecule Pharma Companies Therapies 86

Codon

FEBRUARY 13, 2024

alone, according to the Centers for Disease Control and Prevention. But thankfully there are groups — from charities and start-ups to the non-profit arms of major pharma companies — looking specifically at more public-health-focused approaches to scaling phage therapy for these parts of the world.

Therapies 126

Therapies Virus DNA Clinical Trials 126

Elrig

APRIL 29, 2024

Jasmine has a background in neuroscience and genetic manipulation, with early works focused on using a combined structural and molecular biology approach to assess disease-associated proteins implicated in Alzheimer’s disease. big pharma or startups/spin off? Where do you enjoy more to work? What pro/cons?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

PerkinElmer

FEBRUARY 18, 2021

The top 20 Pharma are moving away from proteins in biochemical assays and overexpressed targets in simple cell lines toward more physiologically relevant assays using primary cells, cocultures, 3-D cell systems, or organoids. Large screens are still in use by leading Pharma. Big screens are still very popular. Full decks up to 1.4M

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

Vial

MARCH 1, 2024

It ensures regulatory compliance for over 15 long-term post-authorization safety studies across eight disease indications. For the fourth consecutive year, PPD, as Thermo Fisher Scientific’s clinical research business, was recognized as the 2023 PharmaTimes Clinical Research Company of the Year.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

Vial

FEBRUARY 19, 2024

At the time, chronic lymphocytic leukemia was really a horrible disease, and only 57 percent of patients had a response. They eventually succumbed to the disease for multiple reasons. Rich McCormick: How do you strike a balance between the clinical aspects and the commercial demands in your role as the CEO of a pharma company?

Small Molecule 52

Small Molecule Therapies Treatment Science 52

Advarra

JULY 19, 2022

The sponsor-initiated IND is conducted by a pharma company seeking commercial approval. If you get approval, then you can conduct clinical trials for other disease indications. Q: When you want to do a study of an FDA-approved drug under an investigational indication, is an IND still required or can you seek an exemption?

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. AB2 Bio – Swiss pharma company AB2 Bio Ltd. named Djordje Filipovic as its new chief commercial officer.

Small Molecule 52

Small Molecule Engineering Clinical Development Pharmaceuticals 52

The Pharma Data

MAY 14, 2021

First, most are on the payroll of the big pharma companies earning lucrative commissions for pushing their drugs…. Shockingly, in many cases, many medications have been found to progress the disease. The second reason is even more common…. Often to the point of no return…. But it is only a partial solution.

Doctors 52

Doctors Production Medical Schools Pharma Companies 52

The Anticancer Fund

JUNE 7, 2022

In the therapeutic study in patients with recurrent and/or metastatic disease (n=12), treatment was shown to be tolerable but there was no signal of efficacy, with median PFS less than two months in 9 evaluable patients. These findings raise more questions of course, but for those of us in repurposing this data-driven approach is welcome.

Drugs 40

Drugs Clinical Trials Trials Treatment 40

Agency IQ

JULY 12, 2024

Intended use includes such things as the condition or disease which the product is meant to treat, the population for whom it is intended, and the route, frequency of administration, and duration of use for the product.

FDA 40

FDA Regulations Production Science 40